Drug intelligence / Profile preview

OAd-NIS

Development stage
Preclinical
Lead developer
University of Minnesota
Modality
Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration
Intratumoral
01

Overview

OAd-NIS is an oncolytic adenovirus engineered with a ∆E3 structure to express the sodium iodide symporter (NIS) as a function of viral replication. Developed by researchers at the University of Minnesota, it features an Ad 5/3 chimeric fiber for optimized binding and transduction in colorectal cancer (CRC) cells and utilizes a Cox2 promoter to drive tumor-specific expression. As a theranostic agent, OAd-NIS enables both diagnostic imaging via radiotracer uptake (e.g., 124I for PET/CT) and therapeutic efficacy when combined with radioactive iodine (e.g., 131I). The virus selectively replicates in and lyses tumor cells while simultaneously concentrating radioactive iodine within the tumor mass, leading to enhanced tumor growth suppression.

Other names
NIS-expressing Oncolytic Adenovirus
02

Targets

CXADR (Coxsackievirus and adenovirus receptor)NIS (Human sodium iodide symporter)αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)

Beyond the preview

Go deeper on OAd-NIS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on OAd-NIS.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call